Botanix Pharmaceuticals (BOT.AX) Stock Price

Botanix Pharmaceuticals Price

ASX·CLOSED
0.02AUD+0.00 (+0.00 %)
Market closed

Over the last 19 years Botanix Pharmaceuticals grew revenue by 24.5% annually, reaching 5.76 M AUD. For Botanix Pharmaceuticals, the net margin of -1,500.6% is up versus -3,211.9% a few years ago. The consensus 12-month price target for Botanix Pharmaceuticals is 0.42 AUD, about 1,891.4% above where the stock trades today. Of 7 analysts, 6 rate the stock a buy — an overall Buy consensus. The stock trades about 17% above its 52-week low.

Botanix Pharmaceuticals stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Botanix Pharmaceuticals over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Botanix Pharmaceuticals stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Botanix Pharmaceuticals's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Botanix Pharmaceuticals Stock Price History
DateBotanix Pharmaceuticals Price
8/5/20260.02 AUD
8/4/20260.02 AUD
8/3/20260.02 AUD
7/31/20260.02 AUD
7/30/20260.02 AUD
7/29/20260.02 AUD
7/28/20260.02 AUD
7/27/20260.02 AUD
7/24/20260.02 AUD
7/23/20260.02 AUD
7/22/20260.02 AUD
7/21/20260.02 AUD
7/20/20260.03 AUD
7/17/20260.03 AUD
7/16/20260.03 AUD
7/15/20260.03 AUD
7/14/20260.03 AUD
7/13/20260.03 AUD
7/10/20260.02 AUD
7/9/20260.02 AUD
7/8/20260.02 AUD
7/7/20260.03 AUD
7/6/20260.02 AUD
7/3/20260.02 AUD
7/2/20260.02 AUD
7/1/20260.02 AUD
6/30/20260.02 AUD
6/29/20260.02 AUD
6/26/20260.02 AUD
6/25/20260.02 AUD
6/24/20260.02 AUD
6/23/20260.02 AUD
6/22/20260.02 AUD
6/19/20260.02 AUD
6/18/20260.02 AUD
6/17/20260.02 AUD
6/16/20260.02 AUD
6/15/20260.02 AUD
6/12/20260.02 AUD
6/11/20260.02 AUD
6/10/20260.02 AUD
6/9/20260.02 AUD
6/5/20260.02 AUD
6/4/20260.02 AUD
6/3/20260.02 AUD
6/2/20260.02 AUD
6/1/20260.02 AUD
5/29/20260.02 AUD
5/28/20260.02 AUD
5/27/20260.02 AUD
5/26/20260.03 AUD
5/25/20260.03 AUD
5/22/20260.03 AUD
5/21/20260.02 AUD
5/20/20260.03 AUD
5/19/20260.03 AUD
5/18/20260.03 AUD
5/15/20260.03 AUD
5/14/20260.03 AUD
5/13/20260.03 AUD
5/12/20260.03 AUD
5/11/20260.03 AUD
5/8/20260.03 AUD
5/7/20260.03 AUD
5/6/20260.03 AUD
5/5/20260.02 AUD
5/4/20260.03 AUD
5/1/20260.03 AUD
4/30/20260.03 AUD
4/29/20260.03 AUD
4/28/20260.03 AUD
4/27/20260.03 AUD
4/24/20260.03 AUD
4/23/20260.03 AUD
4/22/20260.03 AUD
4/21/20260.04 AUD
4/20/20260.04 AUD
4/17/20260.04 AUD
4/16/20260.04 AUD
4/15/20260.04 AUD
4/14/20260.04 AUD
4/13/20260.04 AUD
4/10/20260.04 AUD
4/9/20260.04 AUD
4/8/20260.04 AUD
4/7/20260.04 AUD
4/2/20260.04 AUD
4/1/20260.05 AUD
3/31/20260.04 AUD
3/30/20260.04 AUD
3/27/20260.04 AUD
3/26/20260.04 AUD
3/25/20260.04 AUD
3/24/20260.04 AUD
3/23/20260.04 AUD
3/20/20260.04 AUD
3/19/20260.05 AUD
3/18/20260.05 AUD
3/17/20260.05 AUD
3/16/20260.05 AUD
3/13/20260.05 AUD
3/12/20260.05 AUD
3/11/20260.05 AUD
3/10/20260.05 AUD
3/9/20260.05 AUD
3/6/20260.06 AUD
3/5/20260.06 AUD
3/4/20260.05 AUD
3/3/20260.05 AUD
3/2/20260.05 AUD
2/27/20260.06 AUD
2/26/20260.06 AUD
2/25/20260.06 AUD
2/24/20260.06 AUD
2/23/20260.06 AUD
2/20/20260.06 AUD
2/19/20260.06 AUD
2/18/20260.06 AUD
2/17/20260.07 AUD
2/16/20260.07 AUD
2/13/20260.07 AUD
2/12/20260.07 AUD
2/11/20260.06 AUD
2/10/20260.07 AUD
2/9/20260.07 AUD
2/6/20260.07 AUD
2/5/20260.07 AUD
2/4/20260.07 AUD
2/3/20260.06 AUD
2/2/20260.06 AUD
1/30/20260.06 AUD
1/29/20260.06 AUD
1/28/20260.07 AUD
1/27/20260.07 AUD
1/23/20260.07 AUD
1/22/20260.08 AUD
1/21/20260.08 AUD
1/20/20260.08 AUD
1/19/20260.08 AUD
1/16/20260.08 AUD
1/15/20260.08 AUD
1/14/20260.08 AUD
1/13/20260.08 AUD
1/12/20260.08 AUD
1/9/20260.08 AUD
1/8/20260.08 AUD
1/7/20260.08 AUD
1/6/20260.08 AUD
1/5/20260.08 AUD
1/2/20260.08 AUD
12/31/20250.08 AUD
12/30/20250.07 AUD
12/29/20250.07 AUD
12/24/20250.07 AUD
12/23/20250.07 AUD
12/22/20250.07 AUD
12/19/20250.07 AUD
12/18/20250.07 AUD
12/17/20250.07 AUD
12/16/20250.07 AUD
12/15/20250.07 AUD
12/12/20250.07 AUD
12/11/20250.07 AUD
12/10/20250.06 AUD
12/9/20250.06 AUD
12/8/20250.07 AUD
12/5/20250.07 AUD
12/4/20250.07 AUD
12/3/20250.07 AUD
12/2/20250.07 AUD
12/1/20250.07 AUD
11/28/20250.07 AUD
11/27/20250.07 AUD
11/26/20250.07 AUD
11/25/20250.07 AUD
11/24/20250.07 AUD
11/21/20250.07 AUD
11/20/20250.07 AUD
11/19/20250.07 AUD
11/18/20250.07 AUD
11/17/20250.08 AUD
11/14/20250.08 AUD
11/13/20250.07 AUD
11/12/20250.08 AUD
11/11/20250.07 AUD
11/10/20250.08 AUD
11/7/20250.08 AUD
11/6/20250.07 AUD
11/5/20250.07 AUD
11/4/20250.08 AUD
11/3/20250.08 AUD
10/31/20250.08 AUD
10/30/20250.08 AUD
10/29/20250.08 AUD
10/28/20250.08 AUD
10/27/20250.08 AUD
10/24/20250.09 AUD
10/23/20250.09 AUD
10/22/20250.09 AUD
10/21/20250.09 AUD
10/20/20250.09 AUD
10/17/20250.09 AUD
10/16/20250.09 AUD
10/15/20250.09 AUD
10/14/20250.09 AUD
10/13/20250.09 AUD
10/10/20250.09 AUD
10/9/20250.09 AUD
10/8/20250.09 AUD
10/7/20250.09 AUD
10/6/20250.10 AUD
10/3/20250.10 AUD
10/2/20250.09 AUD
10/1/20250.09 AUD
9/30/20250.09 AUD
9/29/20250.10 AUD
9/26/20250.09 AUD
9/25/20250.09 AUD
9/24/20250.08 AUD
9/23/20250.08 AUD
9/22/20250.08 AUD
9/19/20250.08 AUD
9/18/20250.07 AUD
9/17/20250.08 AUD
9/16/20250.07 AUD
9/15/20250.07 AUD
9/12/20250.07 AUD
9/11/20250.06 AUD
9/10/20250.06 AUD
9/9/20250.08 AUD
9/8/20250.08 AUD
9/5/20250.08 AUD
9/4/20250.08 AUD
9/3/20250.08 AUD
9/2/20250.08 AUD
9/1/20250.09 AUD
8/29/20250.09 AUD
8/28/20250.09 AUD
8/27/20250.09 AUD
8/26/20250.09 AUD
8/25/20250.09 AUD
8/22/20250.09 AUD
8/21/20250.09 AUD
8/20/20250.09 AUD
8/19/20250.09 AUD
8/18/20250.09 AUD
8/15/20250.09 AUD
8/14/20250.09 AUD
8/13/20250.09 AUD
8/12/20250.09 AUD
8/11/20250.09 AUD
8/8/20250.09 AUD
Access this data via the Eulerpool API
Get Free API Key

Botanix Pharmaceuticals Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
168,900.00 AUD
-9.06 M AUD
-9.15 M AUD
Jan 1, 2024
601,800.00 AUD
-12.15 M AUD
-13.87 M AUD
Jan 1, 2025
5.76 M AUD
-88.03 M AUD
-86.40 M AUD
Jan 1, 2026 (e)
34.81 M AUD
-34.81 M AUD
-40.72 M AUD
Jan 1, 2027 (e)
73.83 M AUD
-73.83 M AUD
-20.36 M AUD
Jan 1, 2028 (e)
139.08 M AUD
-139.08 M AUD
13.79 M AUD
Jan 1, 2029 (e)
38.40 M AUD
-38.40 M AUD
63.04 M AUD
Jan 1, 2030 (e)
70.21 M AUD
-70.21 M AUD
0.00 AUD

Botanix Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 7, 2026, 9:49 AM
 
REVENUEM AUD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM AUD
EBITM AUD
EBIT MARGIN%
NET INCOMEM AUD
NET INCOME GROWTH%
SHARESB
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
––––––––––5.0034.0073.00139.0038.0070.00
–––––––––––580.00114.7190.41-72.6684.21
––––––––––40.0040.0040.0040.0040.0040.00
2.002.002.002.002.002.002.002.002.002.002.0013.6029.2055.6015.2028.00
––-4.00-12.00-21.00-24.00-10.00-13.00-9.00-12.00-88.00-34.00-73.00-139.00-38.00-70.00
––––––––––-1,760.00-100.00-100.00-100.00-100.00-100.00
-1.00-1.00-4.00-11.00-17.00-16.00-3.00-13.00-9.00-13.00-86.00-40.00-20.0013.0063.00–
––300.00175.0054.55-5.88-81.25333.33-30.7744.44561.54-53.49-50.00-165.00384.62–
0.080.410.430.490.760.940.970.971.151.501.841.841.841.841.841.84
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Botanix Pharmaceuticals generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Botanix Pharmaceuticals retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Botanix Pharmaceuticals's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Botanix Pharmaceuticals has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Botanix Pharmaceuticals's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Botanix Pharmaceuticals stock margins

The Botanix Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Botanix Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Botanix Pharmaceuticals.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
36.99 %
-9,791.43 %
-3,211.95 %
Jan 1, 2022
36.99 %
-35,157.49 %
-35,216.04 %
Jan 1, 2023
36.99 %
-5,364.36 %
-5,419.78 %
Jan 1, 2024
36.99 %
-2,019.39 %
-2,304.70 %
Jan 1, 2025
36.99 %
-1,528.94 %
-1,500.64 %
Jan 1, 2026 (e)
36.99 %
-100.00 %
-116.96 %
Jan 1, 2027 (e)
36.99 %
-100.00 %
-27.57 %
Jan 1, 2028 (e)
36.99 %
-100.00 %
9.92 %

Botanix Pharmaceuticals Stock Revenue, EBIT, Earnings per Share

The Botanix Pharmaceuticals earnings per share therefore indicates how much revenue Botanix Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.00 AUD
-0.01 AUD
-0.00 AUD
Jan 1, 2022
0.00 AUD
-0.01 AUD
-0.01 AUD
Jan 1, 2023
0.00 AUD
-0.01 AUD
-0.01 AUD
Jan 1, 2024
0.00 AUD
-0.01 AUD
-0.01 AUD
Jan 1, 2025
0.00 AUD
-0.05 AUD
-0.05 AUD
Jan 1, 2026 (e)
0.02 AUD
-0.02 AUD
-0.02 AUD
Jan 1, 2027 (e)
0.04 AUD
-0.04 AUD
-0.01 AUD
Jan 1, 2028 (e)
0.07 AUD
-0.08 AUD
0.01 AUD

Botanix Pharmaceuticals business model & stock analysis

Botanix Pharmaceuticals Ltd is an Australian company specializing in the research and development of innovative therapies based on synthetic cannabinoids. The company was founded in 2014 by a team of experts and is headquartered in Perth, Western Australia. The history of Botanix Pharmaceuticals began with the discovery of the medical properties of cannabinoids derived from the hemp plant. Cannabinoids have a wide therapeutic potential, ranging from pain and inflammation relief to the treatment of seizure disorders and anxiety. Botanix Pharmaceuticals utilizes these properties to develop innovative product candidates that have high efficacy and tolerability. The business model of Botanix Pharmaceuticals is based on the concept of targeted treatment for diseases and conditions where traditional therapies are insufficient or cause unwanted side effects. The company develops and produces medications based on synthetic cannabinoids that target specific disease states and indications. Botanix Pharmaceuticals specializes in two areas. Firstly, it focuses on the development of topical products, such as ointments and creams, that are applied to the skin. These products are particularly effective in treating skin conditions such as acne or psoriasis. Secondly, the company is working on the development of medications for the treatment of internal conditions such as epilepsy or chronic obstructive pulmonary disease (COPD). In the field of topical products, Botanix Pharmaceuticals has already achieved significant success. The company has a promising pipeline of product candidates for various applications, including acne, psoriasis, atopic dermatitis, and bacterial infections. One promising drug candidate is BTX 1503, which was developed for the treatment of severe acne. It contains the synthetic cannabinoid BTX 1308, which possesses anti-inflammatory and antimicrobial properties. BTX 1503 has already demonstrated high efficacy and tolerability in clinical studies. In the field of internal conditions, Botanix Pharmaceuticals collaborates closely with leading institutions and research facilities to develop innovative therapies for seizure disorders and COPD. One promising product candidate is BTX 1801, which was developed for the treatment of severe epilepsy. BTX 1801 contains the synthetic cannabinoid BTX 1204, which has shown high efficacy and tolerability in the treatment of seizures. Botanix Pharmaceuticals is an innovative company that develops highly effective and tolerable medications based on synthetic cannabinoids. The company has already achieved remarkable success in a short period and has established itself as a leading player in the industry. With its pipeline of promising product candidates and its close collaboration with renowned research institutions, Botanix Pharmaceuticals is well-positioned to develop further innovative therapies in the future.

Botanix Pharmaceuticals SWOT Analysis

Strengths

Botanix Pharmaceuticals Ltd has a strong research and development team that is dedicated to discovering innovative solutions in the field of pharmaceuticals. This expertise allows the company to develop unique products with great potential for success in the market.

The company has a portfolio of intellectual property rights and patents, giving it a competitive advantage and protecting its products from potential competitors.

Weaknesses

Botanix Pharmaceuticals Ltd operates in a highly regulated industry, which presents challenges in terms of compliance with strict government regulations. This can result in delays and increased costs in the development and approval process.

The company heavily relies on external funding to support its research and development efforts, making it vulnerable to changes in investor sentiment or the availability of capital.

Opportunities

There is a growing demand for natural and plant-based pharmaceutical products, which aligns with Botanix Pharmaceuticals Ltd's focus on developing treatments derived from botanical sources. This presents an opportunity for the company to capitalize on this trend and gain a significant market share.

The increasing awareness and acceptance of alternative and complementary medicine provide an opportunity for Botanix Pharmaceuticals Ltd to position its products as viable alternatives to traditional pharmaceuticals.

Threats

The pharmaceutical industry is highly competitive, with many established players dominating the market. Botanix Pharmaceuticals Ltd faces the threat of intense competition from both traditional pharmaceutical companies and other biotech firms.

There is also a risk of potential side effects or adverse reactions associated with the use of botanical products. Negative publicity or regulatory concerns related to safety could significantly impact the company's reputation and market position.

Botanix Pharmaceuticals Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Botanix Pharmaceuticals historical P/E ratio, EBIT multiple, and P/S ratio

Botanix Pharmaceuticals annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Botanix Pharmaceuticals shares outstanding

The number of shares of Botanix Pharmaceuticals was 1.84 B in 2025. This indicates how many shares Botanix Pharmaceuticals is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
972.94 M Stocks
Jan 1, 2022
973.14 M Stocks
Jan 1, 2023
1.15 B Stocks
Jan 1, 2024
1.50 B Stocks
Jan 1, 2025
1.84 B Stocks
Jan 1, 2026 (e)
1.84 B Stocks
Jan 1, 2027 (e)
1.84 B Stocks
Jan 1, 2028 (e)
1.84 B Stocks

Botanix Pharmaceuticals stock splits

In Botanix Pharmaceuticals's history, there have been no stock splits.

Botanix Pharmaceuticals Dividend History

3 years of dividend payments

YearAnnual DividendYoY ChangePayments
19960.10AUD↑ 29.0%2×
19950.08AUD↓ 0.4%2×
19940.08AUD—2×

Current Botanix Pharmaceuticals forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
85.71 % (6)
Hold
14.29 % (1)
Sell
0.00 % (0)
12M Price Target
0.42
Last Price
0.02
Currency
AUD
12M Return Potential
1,891.43 %
LTM Return
0 %

Botanix Pharmaceuticals Earnings Calls

Botanix Pharmaceuticals shareholder structure

% Name
8.21913%
Antares Capital Partners Limited
Antares Capital Partners Limited
5.18248%
OC Funds Management Pty Ltd.
OC Funds Management Pty Ltd.
4.94405%
UniSuper Limited
UniSuper Limited
3.78594%
Shenasaby Investments Pty. Ltd.
Shenasaby Investments Pty. Ltd.
1.55121%
Vanguard Investments Australia Ltd.
Vanguard Investments Australia Ltd.
1.04662%
MLC Asset Management
MLC Asset Management

Botanix Pharmaceuticals Beneficial Ownership Filings (SEC 13D/G)

Free Float
72.6%
Float Shares
-
Shares Outstanding
-

Botanix Pharmaceuticals Executives and Management Board

9 members · 22 % women

VI

Mr. Vincent Ippolito

Executive Chairman of the Board, President · since 2019

709,030.00 AUD

Management

HM

Mr. Howie McKibbon

Chief Executive Officer

207,406.00 AUD
GM

Mr. Graeme Morissey

Chief Financial Officer

–
SP

Ms. Susan Park

Company Secretary

–
HH

Ms. Hannah Howlett

Investor Relations · since 2022

–

Board of Directors

MC

Mr. Matthew Callahan

Executive Director · since 2016

347,959.00 AUD
WB

Dr. William Bosch

Executive Director · since 2016

203,537.00 AUD
SW

Dr. Stewart Washer

Non-Executive Director

129,525.00 AUD
DS

Mr. Daniel Sharp

Non-Executive Director

49,665.00 AUD

Frequently asked questions about Botanix Pharmaceuticals

The business model of Botanix Pharmaceuticals Ltd revolves around developing and commercializing innovative pharmaceutical products derived from synthetic cannabidiol (CBD) for the treatment of various skin conditions. With a focus on dermatology, the company aims to unlock the therapeutic potential of CBD to provide effective and safe treatments for acne, atopic dermatitis, and other skin disorders. Botanix Pharmaceuticals utilizes its proprietary drug delivery technology to enhance the skin penetration and bioavailability of CBD, enabling targeted and efficient treatment options. By leveraging the therapeutic properties of CBD, the company aims to address significant unmet medical needs and improve the lives of patients suffering from skin-related ailments.

Botanix Pharmaceuticals Ltd is primarily active in the pharmaceutical and biotechnology industries.

The main competitors of Botanix Pharmaceuticals Ltd in the market include companies such as AcelRx Pharmaceuticals, Cipher Pharmaceuticals, and Zynerba Pharmaceuticals.

Botanix Pharmaceuticals Ltd is a pharmaceutical company specializing in the development of innovative dermatology products. Established in 2014, the company is headquartered in Australia and has emerged as a leading player in the field. With a focus on leveraging the therapeutic potential of synthetic cannabidiol (CBD) for treating skin conditions, Botanix Pharmaceuticals has pioneered groundbreaking research and development in this area. The company's dedication to advancing dermatological solutions has brought forth promising outcomes, making it a key contender in the pharmaceutical industry. Botanix Pharmaceuticals continues to pave the way in discovering safe and effective treatments for various skin-related ailments.

Botanix Pharmaceuticals Ltd has achieved several significant milestones. The company successfully completed Phase 2 clinical trials for their lead product candidate, BTX 1503, which demonstrated promising results in treating acne. In addition, Botanix Pharmaceuticals received approval from the U.S. Food and Drug Administration (FDA) to initiate a Phase 3 clinical trial for BTX 1503. The company also expanded its pipeline by initiating clinical trials for other dermatological conditions, including atopic dermatitis and rosacea. Furthermore, Botanix Pharmaceuticals formed strategic partnerships with leading pharmaceutical companies to enhance its research and development efforts. These milestones reflect the company's commitment to advancing innovative solutions in the field of dermatology.

Botanix Pharmaceuticals Ltd is primarily present in Australia, where it is headquartered. It is also engaged in business activities in the United States, where it operates clinical trials and research collaborations.

Botanix Pharmaceuticals Ltd represents a commitment to innovation, research, and development in the pharmaceutical industry. The company's corporate philosophy revolves around harnessing the potential of natural substances to create effective and safe treatment solutions. With a focus on botanical-based therapies, Botanix Pharmaceuticals aims to provide groundbreaking, evidence-based pharmaceutical products that address unmet medical needs. By combining scientific expertise and a patient-centric approach, the company strives to improve healthcare outcomes and enhance the quality of life for individuals worldwide. Botanix Pharmaceuticals Ltd's dedication to sustainable and ethical practices further underpins its values, ensuring responsible and impactful contributions to the pharmaceutical field.

Analysts currently set an average price target of 0.89 AUD for the Botanix Pharmaceuticals stock (median: 0.42 AUD), implying +4,141.7 % versus the latest price. The consensus is based on 7 analyst ratings.

Botanix Pharmaceuticals Analyst Price Targets 2026

7 analysts currently rate the Botanix Pharmaceuticals stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Botanix Pharmaceuticals to generate revenue of 34.81 M AUD and earnings per share of -0.02 AUD.

Botanix Pharmaceuticals Analyst Price Targets 2026

Converted at the current exchange rate, the Botanix Pharmaceuticals share trades at 0.01 EUR (0.02 AUD).

The Botanix Pharmaceuticals share (BOT.AX) is listed on 2 stock exchanges, including: ASX (BOT.AX).

Botanix Pharmaceuticals Ltd is an Australian biopharmaceutical company specializing in the research and development of cannabinoid-based therapeutics. The company is headquartered in Perth and is listed on the Australian Stock Exchange. Botanix focuses on developing new and innovative treatments based on natural plant compounds to address various medical needs. The company's main focus is on chronic skin conditions and infections such as acne or atopic dermatitis, as well as bacterial infections like MRSA. The company collaborates closely with leading research institutions worldwide and conducts intensive research and development to create a clinically valid pipeline. Botanix's current pipeline includes four key development projects, one of which is already being tested in clinical trials. The first project, BTX 1503, is a topical treatment designed to improve lactic acid production in the skin, which helps prevent or inhibit the growth of bacterial infections. The second project, BTX 1204, aims to treat acne and other chronic skin conditions using synthetic cannabinoids. BTX 1308 is the third project, targeting atopic dermatitis using natural cannabinoids. The fourth and final project, BTX 1801, is a topical antimicrobial gel developed for the treatment of bacteria-induced infections such as MRSA or other skin infections. The company adopts a forward-thinking strategy by exploring the potential of cannabinoids as remedies. The use of cannabinoids offers the advantage of being able to be naturally integrated into the healing process without the serious side effects that can occur with synthetic drugs. Botanix plans to distribute its products worldwide through licensing and other commercial models. Currently, the company is working with strategic partners globally to secure access to international markets and external intellectual property rights. Overall, Botanix's business model is focused on developing innovative therapeutics for a range of diseases based on the unique properties of cannabinoids and plant compounds. The company has an experienced team and collaborates closely with leading research partners to develop a clinically valid pipeline and ultimately provide a safe and effective treatment for patients.

The expected revenue of Botanix Pharmaceuticals is 34.81 M AUD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Botanix Pharmaceuticals is -40.72 M AUD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Botanix Pharmaceuticals is currently -0.95. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Botanix Pharmaceuticals stock.

The price-to-sales ratio (P/S) of Botanix Pharmaceuticals is currently 1.11. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Botanix Pharmaceuticals stock.

The Eulerpool Quality Score for Botanix Pharmaceuticals is 4/10.

The ISIN of Botanix Pharmaceuticals is AU000000BOT2. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Botanix Pharmaceuticals is A2ANJ5. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Botanix Pharmaceuticals is BOT.AX. The ticker symbol is used to trade Botanix Pharmaceuticals shares on the stock exchange.

Botanix Pharmaceuticals pays a dividend, distributed in the months of , , , .

Botanix Pharmaceuticals paid dividends every year for the past 0 years.

Botanix Pharmaceuticals is assigned to the 'Health' sector.

To receive the latest dividend of Botanix Pharmaceuticals from amounting to 0.05 AUD, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

The dividends of Botanix Pharmaceuticals are distributed in AUD.

All fundamentals and in-depth analysis of Botanix Pharmaceuticals

Our stock analysis for Botanix Pharmaceuticals stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Botanix Pharmaceuticals. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Botanix Pharmaceuticals Stock
Botanix Pharmaceuticals Revenue→
Botanix Pharmaceuticals Stock
Botanix Pharmaceuticals Net Income→
Botanix Pharmaceuticals Stock
Botanix Pharmaceuticals P/E→
Botanix Pharmaceuticals Stock
Botanix Pharmaceuticals P/S→
Botanix Pharmaceuticals Stock
Botanix Pharmaceuticals EBIT→
Botanix Pharmaceuticals Stock
Botanix Pharmaceuticals Dividend→
Botanix Pharmaceuticals Stock
Botanix Pharmaceuticals Directors Dealings→
Botanix Pharmaceuticals Stock
Botanix Pharmaceuticals Stocks→
Botanix Pharmaceuticals Stock
Botanix Pharmaceuticals Market capitalization→
Botanix Pharmaceuticals Stock
Botanix Pharmaceuticals Debt→
Botanix Pharmaceuticals Stock
Botanix Pharmaceuticals Liabilities→
Botanix Pharmaceuticals Stock
Botanix Pharmaceuticals Equity→
Botanix Pharmaceuticals Stock
Botanix Pharmaceuticals AAQS→
Botanix Pharmaceuticals Stock
Botanix Pharmaceuticals Employees→
Botanix Pharmaceuticals Stock
Botanix Pharmaceuticals ROE→
Botanix Pharmaceuticals Stock
Botanix Pharmaceuticals ROA→
Botanix Pharmaceuticals Stock
Botanix Pharmaceuticals ROCE→
Botanix Pharmaceuticals Stock
Botanix Pharmaceuticals News→
Botanix Pharmaceuticals Stock
Botanix Pharmaceuticals Analyst Price Targets→

Health Stocks

Boule DiagnosticsBoston ScientificBoundless BioBoryungBPH EnergyBorosil ScientificBPH GlobalBonus BiogroupBrain ScientificBonraybio CoBrainAurora Medical TechnologyBonesupport HoldingAll Stocks A–Z →